Pharmaceutical firm Fresenius Kabi will invest nearly $250m over 10 years to expand its Melrose Park site in Illinois.
The site currently manufactures generic, sterile injectable pharmaceuticals that are used in hospitals and clinics in the US.
The expansion will include construction of several new buildings, which will be connected to the existing manufacturing site.
The expansion plans also include a warehouse for raw materials and components, and an administration building with conference centre, laboratories, office space and cafeteria.
Steven Nowicki, senior vice president of global operations for the company’s North America pharmaceuticals division said: “We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines.”
The multi-stage project is expected to break ground in 2017 and be completed in 2026.
“Our goal is to expand our U.S. manufacturing capabilities while ensuring continued compliance with increasing regulatory and quality requirements and improve production capacity and efficiency,” Nowicki added.